Editas Medicine, Inc.
EDIT Healthcare Biotechnology
Editas Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 25.4% from fiscal 2024. In the quarter to June 2026, revenue grew 232.3%, EPS grew 76.2% and free cash flow grew 40.7%, each against the same quarter a year earlier.
Follow EDIT
Editas Medicine, Inc. (EDIT) EV/Sales
As of 12 October 2026, Editas Medicine, Inc. (EDIT) trades at a EV/Sales of 3.2×. Over the past ten years it has ranged from −4.4× (January 2025) to 295× (April 2016); the current reading is higher than 19% of that period. That is below the Biotechnology industry median of 9.6× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.7× | — |
| FY2024 | −4.1× | — |
| FY2023 | 6.0× | (55.94%) |
| FY2022 | 13.6× | (73.88%) |
| FY2021 | 52.0× | 26.13% |
| FY2020 | 41.2× | (19.82%) |
| FY2019 | 51.4× | 123.36% |
| FY2018 | 23.0× | (70.97%) |
| FY2017 | 79.3× | 20.31% |
| FY2016 | 65.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.4× | 13.35% |
| Mar 2026 | 3.9× | 132.85% |
| Dec 2025 | 1.7× | (56.80%) |
| Sep 2025 | 3.9× | 279.71% |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PRTCY PureTech Health PLC Sponsored ADR compare | −9.1× |
| DMAC DiaMedica Therapeutics, Inc. compare | n/m |
| TECX Tectonic Therapeutic, Inc. compare | n/m |
| RZLT Rezolute, Inc. compare | n/m |
| PRTA Prothena Corporation plc compare | 2.8× |
| EDIT Editas Medicine, Inc. | 3.2× |
| SPRY ARS Pharmaceuticals, Inc. compare | 3.8× |
| CAPR Capricor Therapeutics, Inc. compare | 9.4× |
| ENTX Entera Bio Ltd. compare | 534× |
| Biotechnology industry median | 9.6× |
| Healthcare sector median | 3.5× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)